GLMD

Business Context and Reporting Period

Company: Galmed Pharmaceuticals Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Three and six months ended June 30, 2025
Business Overview: Galmed is a biopharmaceutical company focused on developing Aramchol for liver diseases (NASH/MASH, PSC) and exploring oncological and cardiometabolic indications. The company has no approved products and has not generated product sales revenue. Operations are funded primarily through equity financings.

Key Financial Metrics

Material Changes vs. Prior Period

• Increased Net Loss: Net loss for the six months ended June 30, 2025, increased by 50% to $3.6 million from $2.4 million in the prior year period. This was driven by higher operating expenses and a one-time impairment charge.
• Operating Expenses: Total operating expenses rose 29% to $3.4 million. Research and Development (R&D) expenses increased 45% to $1.7 million due to higher pre-clinical and clinical trial costs. General and Administrative (G&A) expenses increased 15% to $1.7 million, primarily due to higher salary expenses.
• Impairment Charge: The company recognized a $0.5 million impairment loss on its investment in an associate (OnKai Inc.), which did not occur in the comparable 2024 period.
• Capital Raise: The company raised approximately $7.5 million in net proceeds through its At-The-Market (ATM) sales agreement and Standby Equity Purchase Agreement (SEPA), significantly improving liquidity compared to the prior period which had no financing cash flow.
• Share Count: Outstanding shares increased significantly from 1.66 million (Dec 31, 2024) to 5.30 million (June 30, 2025) due to share issuances under the ATM and SEPA programs.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management estimates current cash resources (~$20.6 million in liquid assets) will support operations for more than 12 months from the date of issuance. However, substantial additional capital is required to fund the ARMOR Study, Amilo-5MER program, and future commercialization.
• Strategic Initiatives:
  • Digital Asset Strategy: In August 2025, the Board approved a strategy to potentially allocate up to 50% of cash reserves to digital assets (e.g., Bitcoin, Ethereum), engaging Tectona Ltd. for management.
  • SEDDS Partnership: Terminated a binding term sheet for an exclusive license of a Self-Emulsifying Drug Delivery System (SEDDS). Instead, the company plans to invest up to $2 million for a 20% stake in a new UK-based entity developing the technology.
• Key Risks:
  • Geopolitical Instability: Operations are based in Israel. Ongoing conflicts involving Hamas, Hezbollah, and Iran pose risks to operations, employee availability (military reserve duty), and insurance coverage.
  • Capital Requirements: Failure to secure additional financing could force delays or elimination of R&D programs, raising doubts about the company's ability to continue as a going concern.
  • Regulatory and Development Risk: No products are approved; success depends on clinical trial outcomes and regulatory approvals which are uncertain.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $20.6 million liquid asset position against the projected burn rate for the ARMOR Study and new digital asset strategy.
• Dilution Impact: Assess the impact of the recent share issuances (increasing share count from ~1.7M to ~5.3M) on existing shareholder value.
• Digital Asset Exposure: Review the specifics of the new treasury policy regarding the potential 50% allocation to volatile digital assets and the associated risks.
• Impairment Details: Investigate the qualitative factors leading to the $0.5 million impairment of the OnKai Inc. investment.
• Geopolitical Contingency: Evaluate the company's business continuity plans regarding the security situation in Israel and potential disruptions to clinical trials or supply chains.